Sugammadex

Generic Name: Sugammadex

Brand Names: Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal

Drug Type: Small Molecule

Chemical Formula: C_₇₂H_₁₁₂O_₄₈S_₈

CAS Number: 343306-71-8

Unique Ingredient Identifier: 361LPM2T56

Background: Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.

Indication: Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.

Associated Conditions: Neuromuscular blockade caused by vecuronium bromide

Associated Therapies: -

Clinical Trials

Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: Rocuronium
Drug: Succinylcholine
Drug: Cisatracurium
Drug: Mivacurium
Device: Objective neuromuscular monitoring (acceleromyography)
Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2016-09-26

Last Posted Date: 2019-09-12

Lead Sponsor: Jakob Louis Thomsen

Target Recruit Count: 30430

Registration Number: NCT02914119

Locations: 🇩🇰
Herlev Hospital, Herlev, Denmark

Quality of Recovery After Reversal With Neostigmine or Sugammadex.

Phase 4

Completed

Conditions: Incomplete Reversal of Neuromuscular Block

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2016-09-21

Last Posted Date: 2020-05-22

Lead Sponsor: Stony Brook University

Target Recruit Count: 80

Registration Number: NCT02909439

Locations: 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States

The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications

Phase 4

Completed

Conditions: Neuromuscular Blockade
Postoperative Complications

Interventions: Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2016-08-10

Last Posted Date: 2020-03-31

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 200

Registration Number: NCT02861131

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency

Phase 4

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: Neostigmine
Drug: sugammadex
Drug: Glycopyrrolate

First Posted Date: 2016-08-09

Last Posted Date: 2019-04-12

Lead Sponsor: University of South Florida

Target Recruit Count: 50

Registration Number: NCT02860507

Effect of Neuromuscular Blockade and Reversal on Breathing

Phase 4

Completed

Conditions: Respiratory Insufficiency

Interventions: Drug: Placebo
Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2016-07-27

Last Posted Date: 2020-02-19

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 46

Registration Number: NCT02845375

Locations: 🇳🇱
Leiden University Medical Center, Leiden, ZH, Netherlands

Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

Phase 4

Terminated

Conditions: Pulmonary Complications

Interventions: Drug: Neostigmine/Glycopyrrolate
Drug: Sugammadex

First Posted Date: 2016-07-07

Last Posted Date: 2023-03-29

Lead Sponsor: Northern Sydney Anaesthesia Research Institute

Target Recruit Count: 30

Registration Number: NCT02825576

Locations: 🇦🇺
Royal North Shore Hospital, St Leonards, New South Wales, Australia

Atropine in Laparoscopic Gynaecological Surgery

Phase 4

Conditions: Gynecology
Laparoscopic Surgery

Interventions: Drug: Placebo
Drug: Atropine
Drug: Sevoflurane
Drug: sugammadex
Drug: Ketorolac
Drug: Morphine PCA
Drug: rocuronium
Drug: propofol

First Posted Date: 2016-05-11

Last Posted Date: 2016-05-11

Lead Sponsor: Clinica Santa Maria

Target Recruit Count: 150

Registration Number: NCT02769325

Locations: 🇨🇱
Clinica Santa Maria, Santiago, Chile

Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

Phase 4

Completed

Conditions: General Surgery

Interventions: Drug: Placebo
Drug: Sugammadex

First Posted Date: 2016-04-05

Last Posted Date: 2022-07-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 260

Registration Number: NCT02728726

Locations: 🇺🇸
The University of Texas, UTHealth, Houston, Texas, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States

Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

Phase 4

Completed

Conditions: Brain Cancer

Interventions: Drug: Sugammadex

First Posted Date: 2016-03-15

Last Posted Date: 2016-03-15

Lead Sponsor: Baskent University

Target Recruit Count: 26

Registration Number: NCT02708056

Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography

Phase 4

Conditions: Post-operative Residual Curarization

Interventions: Drug: Sugammadex
Device: Diaphragm Ultrasonography
Drug: Neostigmine
Device: Neurumuscual monitoring
Drug: Atropine
Drug: Rocuronium
Drug: Fentanyl
Drug: Propofol
Drug: Sevoflurane

First Posted Date: 2016-03-04

Last Posted Date: 2016-10-25

Lead Sponsor: University of Florence

Target Recruit Count: 58

Registration Number: NCT02698969

Locations: 🇮🇹
Azienda Ospdaliero Universitaria Careggi, Florence, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy